Interní Med. 2016; 18(5): 260-262
What do the data from real practice of using novel anticoagulants suggest? Focus on apixaban
- Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
The European Society of Cardiology (ESC 2016) annual congress took place in Rome from 27th to 31st of August 2016. It is the world’s largest cardiology congress that hosted 32,897 attendees from all over the world this year. A total of 11,000 abstracts were presented and around 500 expert sessions were held during the congress. The lectures were dedicated to the latest developments in cardiovascular medicine and to the presentation of the new ESC guidelines. One of the central topics in the field of arrhythmology was the management of atrial fibrillation, including antithrombotic prophylaxis. Also presented at the congress were a number of abstracts dealing with antithrombotic treatment in non-valvular atrial fibrillation. Likewise, a number of review lectures were delivered or data from various databases were presented. This brief review introduces the most important information from this area.
Keywords: atrial fibrillation, antithrombotic treatment, anticoagulants, apixaban
Published: December 1, 2016 Show citation
References
- Lip GYH, Keshishian A, Kamble S, et al. Is major bleeding risk for oral anticoagulants similar between nonvalvular atrial fibrillation patients newly initiated on warfarin and propensity score matched NOAC initiators? A real world study. Abstract: P2543. Eur Heart J 2016; 37(Abstract Supplement): 493.
- Lip GYH, Keshishian A, Kamble S, et al. Major bleeding risk in patients 75 years of age or older with nonvalvular atrial fibrillation initiating oral anticoagulants: a real world comparison of warfarin, apixaban, dabigatran, or rivaroxaban. Abstract: P2567. Eur Heart J 2016; 37(Abstract Supplement): 500-501.
- Halvorsen S. Lecture at ESC 2016, FP 2951. Available at: http://congress365.escardio.org/Search-Results?vgnextkeyword=Halvorsen#.WBjGuOmQyUl.
- Lin I, Masser ia C, Mardekian J, et al. Bleeding risk for nonvalvular AF patients prescribed warfarin, or standard doses of apixaban 5 mg BID, dabigatran 150 mg BID or rivaroxaban 20 mg QD in real world practice: Findings from EHR. Abstract: 2065. Eur Heart J 2016; 37(Abstract Supplement): 402.
- Yao X, Abraham NS, Sangaralingham RL, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation J Am Heart Assoc. 2016; 5: e003725 doi: 10.1161/JAHA.116.003725.
Go to original source... 
Go to PubMed...